3-(4-bromophenoxy)oxetane | 1369534-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(4-bromophenoxy)oxetane
• CAS: 1369534-96-2
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: KTHYKLLJTJDHER-UHFFFAOYSA-N

物化性质

• 沸点：
  297.2±30.0 °C(Predicted)
• 密度：
  1.550±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-bromophenoxy)oxetane 在 四(三苯基膦)钯 、 水 、 sodium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 (2E,4Z)-N-(3-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienamide
  参考文献：
  名称：

  Discovery of Novel 5,5-Diarylpentadienamides as Orally Available Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists

  摘要：

  We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the S-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the S-position increases their ability to penetrate the blood brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.

  DOI：

  10.1021/jm300101n
• 作为产物：
  描述：

  2-(4-bromophenoxy)-1,3-diacetoxypropane 在 水 、 sodium hydride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 mineral oil 为溶剂， 反应 51.17h， 生成 3-(4-bromophenoxy)oxetane
  参考文献：
  名称：

  Discovery of Novel 5,5-Diarylpentadienamides as Orally Available Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists

  摘要：

  We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the S-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the S-position increases their ability to penetrate the blood brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.

  DOI：

  10.1021/jm300101n

文献信息

• [EN] PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS<br/>[FR] COMPOSÉS DE PYRAZOLE ET LEUR UTILISATION EN TANT QUE BLOQUEURS DES CANAUX CALCIQUES DE TYPE T
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015186056A1

  公开（公告）日：2015-12-10

  The invention relates to compounds of formula (I) Formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

  这项发明涉及式(I)的化合物。式(I)中X、Y、R1、R2、(R4)n和(R5)m的定义如描述中所述，并且涉及这些化合物的药用盐。这些化合物可用作钙T通道阻滞剂。
• INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK
  申请人：PFIZER INC.

  公开号：US20130267493A1

  公开（公告）日：2013-10-10

  The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

  本发明涉及激活5'-腺苷单磷酸活化蛋白激酶（AMPK）的吲哚和吲唑化合物的化学式（I）。该发明还包括含有这些化合物的药物组合物以及治疗或预防通过激活AMPK改善的疾病、症状或疾病的方法。
• FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
  申请人：REILLY Usa

  公开号：US20120232083A1

  公开（公告）日：2012-09-13

  The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

  本发明涉及一种新型羟羧酸衍生物的类别，其作为LpxC抑制剂的用途，更具体地说，其用于治疗细菌感染。
• 含氮稠合三环衍生物及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN111072675A

  公开（公告）日：2020-04-28

  本发明公开了含氮稠合三环衍生物及其用途，具体地，本发明涉及一类新颖的含氮稠合三环衍生物以及包含该类化合物的药物组合物，可作为选择性腺苷A2A受体拮抗剂。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在制备治疗与腺苷A2A受体相关的疾病，特别是帕金森病的药物中的用途。
• Mild C–C Bond Formation via Lewis Acid Catalyzed Oxetane Ring Opening with Soft Carbon Nucleophiles
  作者：Hai Huang、Tianyu Zhang、Jianwei Sun

  DOI：10.1002/anie.202013062

  日期：2021.2

  C−C bond formation. In the presence of LiNTf2 or TBSNTf2 as catalyst, silyl ketene acetals were found to be effective nucleophiles to generate a wide range of highly oxygenated molecules, which are key substructure in natural products like polyketides. Furthermore, intramolecular oxetane opening by a styrene‐based carbon nucleophile via a Prins‐type process was also achieved with Sc(OTf)3 as catalyst

  已经开发出通过软碳亲核试剂温和的氧杂环丁烷打开的方法，可有效形成C-C键。在存在LiNTf 2或TBSNTf 2作为催化剂的情况下，发现甲硅烷基乙烯酮缩醛是有效的亲核试剂，可产生多种高度氧化的分子，这些分子是天然产物（如聚酮化合物）的关键亚结构。此外，还使用Sc（OTf）3作为催化剂，通过Prins型工艺通过苯乙烯基碳亲核试剂打开了分子内氧杂环丁烷，从而有效地形成了有用的2,3-二氢苯并[b]氧杂环丁烷骨架。